Sentences with phrase «treatment programs in the country»

One of 130 such alcohol treatment programs in the country, this one has sought to incorporate Indian tradition and spirituality into its approach.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

This report summarizes the WHO approach to drug dependence and describes treatment, education, training, and research programs in various countries.

HIV Medicine DOI: 10.1111/j.1468-1293.2011.00918.x IBFAN - Asia Position Statement on HIV and Infant Feeding, 13 October 2008 South African Tshwane Declaration on breastfeeding, S Afr J Clin Nutr 2011; 24 (4) UNAIDS 2010, Strategy Getting to Zero, UNAIDS Strategy 2011 — 2015 UNAIDS 2010, Agenda for Accelerated Country Action for Women, Girls, Gender Equality and HIV, 2010 - 2014 UNAIDS 2011, Countdown to Zero: Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive, 2011 - 2015 UNAIDS 2011 Press Release, 9 June, World leaders launch plan to eliminate new HIV infections among children by 2015 UNICEF Convention on the Rights of the Child UNICEF 2010, Facts for Life UNICEF 2011, Programming Guide, Infant and Young Child Feeding, 26 May 2011 WHO / UNICEF 2003, Global strategy for infant and young child feeding WHO 2007, Evidence on the long - term effects of breastfeeding: systematic reviews and meta - analysis WHO, UNAIDS, UNICEF 2009, Towards universal access: scaling up priority HIV / AIDS interventions in the health sector: progress report 2009 WHO 2009, Women and health, Today's evidence tomorrow's agenda WHO 2009, Acceptable medical reasons for use of breast - milk substitutes WHO 2009, Rapid advice: use of antiretroviral drugs for treating pregnant womenand preventing HIV Infection in infants WHO 2009, Rapid advice: revised WHO principles and recommendations on infant feeding in the context of HIV WHO 2010, Priority Interventions — HIV / AIDS prevention, treatment and care in the health sector WHO 2010, Guidelines on HIV and infant feeding: Principles and recomendations for infant feeding in the context of HIV and a summary of evidence WHO 2010, Annexure 7b to Guidelines on HIV and infant feeding.

Established in 2000, the Fetal Treatment Program has helped more than 70 families from across the country.

The drug, which has rapidly spread across the country in recent years, was the subject of a large package of programs and policies outlined on Tuesday, including easing access to treatment, expanding wraparound recovery services and limiting opioid prescriptions for acute pain to seven days, with some exceptions.

Since its founding in 1982, Komen has funded more than $ 800 million in research and provided more than $ 1.6 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 30 countries worldwide.

«Countries using these measures should instead increase the availability of proven opioid - agonist therapies, such as methadone, and ensure there is adequate access to voluntary treatment programs in community settings and facilitate people with opioid addiction to seek treatment.»

Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports.

People in addiction treatment programs around the world use tobacco at two to three times the rate of people who are not being treated for addiction, according to a review of research studies from 20 countries other than the United States.

Just over half (52 per cent) of the countries with evidence of injecting drug use had needle syringe programs and medical treatment to encourage reductions in injecting — opioid substitution therapy — was available in less than half of all countries identified (48 per cent).

Plans are now taking shape for an elaborate testing program of the new H1N1 vaccines in the United States, funded in part by the National Institutes of Health and carried out at the Vaccine and Treatment Evaluation Units, a network of clinical centers around the country.

After working in inpatient and residential programs using a cognitive - behavioral approach, she was a co-founder of the OCD Institute when it opened in 1997 as the first residential treatment program for OCD in the country.

Each country program has created a strong network of service providers rapidly expanding the provision of prevention, care and treatment in their region.

C.S. Mott Children's Hospital was the first comprehensive TIS treatment program in Michigan, and among the first in the nation, to give children with thoracic insufficiency syndrome access to the groundbreaking VEPTR device and we continue to be one of the most experienced VEPTR programs in the country.

In this capacity, she provided technical assistance and strategic advice on the development of laboratory plans and systems to support national HIV / AIDS prevention, care and treatment programs in the Initiative's partner countries in Sub-Saharan AfricIn this capacity, she provided technical assistance and strategic advice on the development of laboratory plans and systems to support national HIV / AIDS prevention, care and treatment programs in the Initiative's partner countries in Sub-Saharan Africin the Initiative's partner countries in Sub-Saharan Africin Sub-Saharan Africa.

Loyola Medicine's Urogynecology & Reconstructive Pelvic Surgery Program was the first of its kind in the greater Chicago area — and is still one of the few programs in the country — to offer single - site location for the multidisciplinary diagnosis and treatment of urogynecological disorders and pelvic - floor dysfunction for women.

Southern Research's anti-HIV screening program became the largest in the country, and many of the AIDS treatments now on the market were evaluated through its program.

U-M implanted the first VEPTR device for treatment of congenital scoliosis in the state of Michigan in 2006, and is still among the largest VEPTR programs in the country.

3/1/2007 National Eating Disorders Expert Offers New Anorexia Treatments at UCSD San Diego treatment program for families only one of its kind in the country A nationally recognized authority on eating disorders says that an intervention program designed for families of anorexic patients offers promising treatment of a disease... More...

University of Michigan C.S. Mott Children's Hospital is one of the leading multidisciplinary programs for comprehensive treatment of vascular anomalies in the country.

But shes found some relief with a combination of three medications and an intensive in - patient treatment program at McLean Hospital, one of two in the country.

WASHINGTON, DISTRICT OF COLUMBIA, June 14, 2016 — American Humane, the country's first national humane organization, and the first to create historic protections for animals on farms and ranches, film and television, and other environments where animals live in human care, is announcing today the launch of a global program dedicated to helping ensure the welfare and humane treatment of the remarkable, endangered and disappearing animals living in the world's zoos and aquariums.

NC State's equine program provides expert care for colic at the country's preeminent center for excellence in treatment.

Rather than spending money in remedial programs, we would do well to help developing countries with their infrastructures: sewage treatment, clean water, minimal electricity, agricultural supplies, etc...

Such programs need to have safeguards for Indigenous rights built in to all aspects of operations to avoid developed countries exporting their treatment of Indigenous peoples along with their emissions problems.

The guide is designed to assist healthcare providers, SUD treatment providers, child welfare programs and judicial systems to improve their collaborative practice, and to offer information about additional resources that will strengthen their capacity to provide coordinated, best - practice care and services Collaborative planning and implementation of services that reflect best practices for treating opioid use disorders during pregnancy are yielding promising results in communities across the country..

«Simply put, eliminating the national family planning program will result in millions of women across the country losing access to basic primary and preventive health care, such as lifesaving cancer screenings, contraception, HIV testing and counseling, STI testing and treatment, and annual exams.

STARTTS, The NSW Service for the Treatment and Rehabilitation of Torture and Trauma Survivors STARTTS, The NSW Service for the Treatment and Rehabilitation of Torture and Trauma Survivors, has developed the following resources for those involved in counselling children and families from refugee backgrounds: Settling In, a group program for newly arrived refugee and migrant students which aims to help students adjust to life in Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin counselling children and families from refugee backgrounds: Settling In, a group program for newly arrived refugee and migrant students which aims to help students adjust to life in Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrIn, a group program for newly arrived refugee and migrant students which aims to help students adjust to life in Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin their new country.

He has developed a number of empirically supported treatment programs that are used by researchers and therapists in countries across the world and have been honoured by awards from both scientific and consumer groups.

STARTTS, The NSW Service for the Treatment and Rehabilitation of Torture and Trauma Survivors has developed the following resources for those involved in counselling children and families from refugee backgrounds: Settling In, a group program for newly arrived refugee and migrant students which aims to help students adjust to life in Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin counselling children and families from refugee backgrounds: Settling In, a group program for newly arrived refugee and migrant students which aims to help students adjust to life in Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrIn, a group program for newly arrived refugee and migrant students which aims to help students adjust to life in Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin Australia, and Families in Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin Cultural Transition (FICT), a ten week series of workshops designed to help newly arrived refugees learn about Australia and settle successfully in their new countrin their new country.

AHN has one of the few programs in the country offering an intensive outpatient program for new moms struggling with depression or anxiety, and keeping mother and baby together during treatment.

The OCDI Jr. is one of only two programs in the country to provide this form of residential evidence - based treatment for anxious youth.

The Sunshine Kids, headquartered in Houston, TX, provides a variety of programs and events, free of charge, for kids who are receiving cancer treatments in hospitals across North America.It has sent thousands of children with cancer to vacation and recreation areas throughout the country.